A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
To evaluate an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A personalized vaccine, consisting of between 4 to 20 synthetic long peptides, will be generated for each patient and shall be administered as an adjuvanted vaccine, with the adjuvant Hiltonol.